During a Targeted Oncology™ Case-Based Roundtable™ event, Atish D. Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discussed with participants about selecting next-line therapy for metastatic castration-resistant prostate cancer after use of enzalutamide and docetaxel.
During a Targeted Oncology™ Case-Based Roundtable™ event, David Zhen, MD, explored treatment options for patients with advanced HER2-negative upper gastrointestinal cancers.
During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua Richter, MD, and participants discussed second-line therapy options for a patient with high-risk relapsed multiple myeloma after frontline lenalidomide, bortezomib, and dexamethasone followed by autologous stem cell transplant.
During a Targeted Oncology™ Case-Based Roundtable™ event, Gabriela S. Hobbs, MD, reviewed the data for frontline use of JAK inhibitors to treat patients with primary myelofibrosis.
During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed the importance of patient characteristics and biomarkers in choosing an immunotherapy-containing regimen for patients with non–small cell lung cancer, particularly if their PD-L1 expression is low. This is the first of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Aditya Bardia, MD, MPH, discussed treatment approaches for a patient with hormone receptor–positive, HER2- negative metastatic breast cancer?
In the second article of a 2-part series, Joyce O’Shaughnessy, MD, discusses the most recent findings from the phase 3 EMERALD study for patients with hormone receptor–positive metastatic breast cancer.
During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed biopsy and treatment approaches for a patient diagnosed with T2aN2M0, stage IIIA adenocarcinoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Martin F. Dietrich, MD, PhD, discussed the phase 2 data for osimertinib plus chemotherapy in EGFR-mutated non–small cell lung cancer and what they suggest for the upcoming phase 3 FLAURA2 trial results.
During a Targeted Oncology™ Case-Based Roundtable™ event, Sandy Liu, MD, discussed the frontline tyrosine kinase inhibitor/immune checkpoint inhibitor regimens and how to manage toxicities related to these regimens.
In the first article of a 2-part series, Aditya Bardia, MD, MPH, leads a discussion on what factors influence sequencing treatment for patients with estrogen receptor positive advanced breast cancer.
At a live virtual event, Rahul Aggarwal, MD, discussed the addition of olaparib to the treatment of patients with metastatic castration-resistant prostate cancer harboring certain gene mutations.
During a Targeted Oncology™ Case-Based Roundtable™ event, April K.S. Salama, MD, discussed treatment approaches for a 78-year-old patient with metastatic melanoma discovered 12 years after surgical resection.
In the first article of a 2-part series, Sumanta K. Pal, MD, leads a discussion on considerations for the treatment of patients with relapsed/refractory renal cell carcinoma in the third-line setting.
During a Targeted Oncology™ Case-Based Roundtable™ event, Carrie L. Kitko, MD, discussed whether to biopsy a patient with chronic GVHD and what treatment to use following steroids.
In the first article of a 2-part series, Mehmet A. Blien, MD, discusses where cabazitaxel fits into the treatment paradigm for patients with metastatic castration resistant prostate cancer.
During a Targeted Oncology™ Case-Based Roundtable™ event, Jubilee Brown, MD, discussed the treatment options for a patient with endometrial cancer who relapsed following resection and again following a complete response to chemotherapy. This is the first of 2 articles based on this event.
In the first article of a 2-part series, Rana McKay, MD, goes through the updated data from the CheckMate 9ER trial that supports the continued use of the combination of nivolumab and cabozantinib for patients with metastatic clear cell renal cell carcinoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Brad Haverkos, MD, and other participants discussed the role of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma. This is the second of 2 articles based on this event.
In this first part of a 2-article series, Joyce O’Shaughnessy, MD, recent updates to treatment and testing guidelines for patients with advanced breast cancer whose disease harbors an ESR1 mutation.
During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, and other physicians discussed how to manage toxicities and counsel patients when using selinexor for relapsed/refractory multiple myeloma.
In the second article of a 2-part series, Joseph M. Tuscano, MD, discusses with fellow clinicians what to do for a patient that doesn’t want to undergo CAR T-cell therapy to treat their early-relapse diffuse large B-cell lymphoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Renuka Iyer, MD, discussed subgroup analyses of the HIMALAYA trial of frontline durvalumab plus tremelimumab for patients with hepatocellular carcinoma. This is the second of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Brad Haverkos, MD, and other participants discussed the choice of treatment options for a patient with relapsed/refractory diffuse large B-cell lymphoma who previously received R-CHOP and pola-BR.
During a Targeted Oncology™ Clinical Case Forum™ event, Lyndsay Willmott, MD, discussed the data supporting the use of PARP inhibitors as primary maintenance therapy for patients with ovarian cancer.
In separate live, virtual events, Hussein A. Tawbi, MD, PhD; and Allison Betof Warner, MD, PhD, discuss potential treatment options for a patient with BRAF mutation–negative melanoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Ticiana Leal, MD, discussed treatment options for recurrent extensive-stage small cell lung cancer, including topotecan, lurbinectedin, and platinum rechallenge.
During a Targeted Oncology™ Case-Based Roundtable™ event, Daniel Pollyea, MD, MS, and participants discussed the diagnosis and treatment of a patient with blastic plasmacytoid dendritic cell neoplasm.
During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, discussed the case of a patient who relapsed after receiving first- and second-line regimens for multiple myeloma. This is the first of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Tian Zhang, MD, and participants discussed factors that drive their choice of first-line therapy for patients with advanced renal cell carcinoma.